Land and Houses PCL
Land and Houses PCL operates in the real estate rental, development, and operations industry, generating revenue primarily through property development and management activities.
Business. Land and Houses PCL (LH.BK) is a real estate company engaged in rental, development, and operations activities. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
13 analysts · consensus Hold- DividendDividend USD 0.72/sh2026-09-11
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- DividendDividend USD 0.72/sh2026-09-11
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressApril McClain Delaney — Labcorp Holdings Inc. Common Stock2026-02-11 · MD · Purchase · $1,001 - $15,000
- CongressApril McClain Delaney — Labcorp Holdings Inc. Common Stock2026-02-04 · MD · Purchase · $1,001 - $15,000
- CongressApril McClain Delaney — Labcorp Holdings Inc. Common Stock2026-01-28 · MD · Purchase · $1,001 - $15,000
- CongressApril McClain Delaney — Labcorp Holdings Inc. Common Stock2025-11-17 · MD · Purchase · $1,001 - $15,000
- CongressApril McClain Delaney — Labcorp Holdings Inc. Common Stock2025-10-31 · MD · Purchase · $1,001 - $15,000
- CongressApril McClain Delaney — Labcorp Holdings Inc. Common Stock2025-10-29 · MD · Purchase · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Land and Houses PCL (LH.BK) is a real estate company engaged in rental, development, and operations activities. The firm is headquartered in Thailand and is primarily listed on the Stock Exchange of Thailand. Specific details regarding operating segments and geographic revenue mix are not available.
Land and Houses PCL maintains a debt-to-equity ratio of 1.53, indicating a moderate reliance on debt financing, which is in line with the industry norms for real estate firms. The company's liquidity position is characterized as medium, with a current ratio of 1.95, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is negative at -2.57 billion THB, reflecting ongoing capital expenditures of -4.57 billion THB, which are typical for a development-focused real estate company.
Profitability metrics show a return on equity (ROE) of 7.16% and a return on assets (ROA) of 2.64%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming in terms of asset and equity utilization compared to its peers. The operating margin of 13.77% (calculated from operating income of 2.86 billion THB on revenue of 20.75 billion THB) is in line with the industry average, but the net profit margin of 17.90% is slightly above average, suggesting effective cost control in the operating and pre-tax phases.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes, which could impact revenue stability. The company's operations are entirely within Thailand, and there is no indication of international expansion in the latest financial reports.
Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The current fiscal year revenue of 20.75 billion THB is expected to remain relatively flat, with a marginal increase or decrease of less than 5% in the following year. This conservative outlook is supported by the company's capital structure and the current economic environment in Thailand.
The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is low, with no significant dilution expected in the near term. The company has not issued additional shares recently, and there are no indications of a pending equity offering or share buyback program. The absence of dilution risk is a positive factor for shareholders, as it preserves ownership concentration and earnings per share.
Recent events, including analyst estimates and recommendations, suggest a mixed outlook for the company. The mean price target of 3.86 THB and the median price target of 3.95 THB indicate a cautious but not overly optimistic view from analysts. The mean recommendation score of 3.23, with 8 hold ratings and 1 strong buy rating, reflects a generally neutral stance, with no strong consensus for either a buy or sell recommendation. These signals suggest that while the company is not expected to underperform significantly, it is also not seen as a high-growth opportunity in the near term.
- Land and Houses PCL has a debt-to-equity ratio of 1.53, indicating a moderate reliance on debt financing.
- The company's ROE of 7.16% is below the industry median, suggesting underperformance in equity utilization.
- Free cash flow is negative at -2.57 billion THB, reflecting ongoing capital expenditures.
- The company's revenue is concentrated in a single business segment with no geographic diversification.
- Analysts have a generally neutral outlook, with a mean price target of 3.86 THB and a mean recommendation score of 3.23.
- The company faces medium liquidity risk and low dilution risk, with no significant dilution expected in the near term.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,32 |
| Revenue | —no estimate | —no estimate | 23,6B THB |
| Operating income | —no estimate | —no estimate | 2,0B THB |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- EVP, Chief Legal Officer · Restricted Stock Unit → Common StockDisposed 256exercise · 2026-07-01
- EVP and President, Diagnostics · Restricted Stock Unit → Common StockDisposed 327exercise · 2026-07-01
- SVP, Chief Accounting Officer · Restricted Stock Unit → Common StockDisposed 536exercise · 2026-02-11
- Director, President & CEO · Restricted Stock Unit → Common StockDisposed 3 656exercise · 2026-02-11
- EVP, Pres Diagnostics & COO · Restricted Stock Unit → Common StockDisposed 806exercise · 2026-02-11
- EVP, Corporate Affairs · Restricted Stock Unit → Common StockDisposed 376exercise · 2026-02-11
- Chief Financial Officer, EVP · Restricted Stock Unit → Common StockDisposed 860exercise · 2026-02-11
- EVP, Diagnostics · Restricted Stock Unit → Common StockDisposed 323exercise · 2026-02-11
- SVP, Chief Accounting Officer · Restricted Stock Unit → Common StockDisposed 160exercise · 2026-02-11
- EVP, Chief Marketing Officer · Restricted Stock Unit → Common StockDisposed 230exercise · 2026-02-11
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Land and Houses PCL Market data — financials · 2026-05-28
- Land and Houses PCL Market data — analyst estimates · 2026-05-28
- Land and Houses PCL Market data — ESG · 2026-05-28
Ownership & reference
Leadership
- Naporn SunthornchitcharoenExecutive Chairman of the Board
Insider activity
- EVP and President, Diagnostics · Common StockSold 234 @ $286,19$67K · 2026-07-02
- EVP, Chief Legal Officer · Common StockSold 92 @ $286,19$26K · 2026-07-02
- EVP and President, Diagnostics · Common StockOther 93 @ $283,88$26K · 2026-07-01
- EVP, Chief Legal Officer · Common StockOther 256 · 2026-07-01
- EVP, Chief Legal Officer · Common StockOther 73 @ $283,88$21K · 2026-07-01
- EVP and President, Diagnostics · Common StockOther 327 · 2026-07-01
- EVP, Chief Legal Officer · Common StockSold 762 @ $263,89$201K · 2026-06-08
- Director, President & CEO · Common StockSold 5 903 @ $254,50$1,5M · 2026-05-11
- SVP, Chief Accounting Officer · Common StockSold 1 633 @ $267,05$436K · 2026-03-27
- EVP, Operations · Common StockSold 839 @ $267,05$224K · 2026-03-27
- EVP, Operations · Common StockOther 2 388 · 2026-03-26
- EVP, Operations · Common StockOther 711 @ $268,38$191K · 2026-03-26
- EVP, Chief Legal Officer · Common StockOther 1 584 · 2026-03-26
- EVP, Chief Legal Officer · Common StockOther 451 @ $268,38$121K · 2026-03-26
- EVP, Pres, Central Labs & Intl · Common StockOther 1 184 · 2026-03-26
- EVP, Pres Diagnostics & COO · Common StockOther 9 304 · 2026-03-26
- EVP, Pres, Central Labs & Intl · Common StockOther 481 @ $268,38$129K · 2026-03-26
- EVP, Pres Diagnostics & COO · Common StockOther 4 600 @ $268,38$1,2M · 2026-03-26
- EVP, Pres Diagnostics & COO · Common StockOther 2 968 · 2026-03-26
- EVP, Pres Diagnostics & COO · Common StockOther 1 468 @ $268,38$394K · 2026-03-26
- EVP, Pres of ED, CMO & CSO · Common StockOther 9 304 · 2026-03-26
- EVP, Pres of ED, CMO & CSO · Common StockOther 4 042 @ $268,38$1,1M · 2026-03-26
- EVP, Pres of ED, CMO & CSO · Common StockOther 1 986 · 2026-03-26
- EVP, Pres of ED, CMO & CSO · Common StockOther 863 @ $268,38$232K · 2026-03-26
- SVP, Chief Accounting Officer · Common StockOther 2 388 · 2026-03-26
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): 10.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
- Net margin (FY 2025-12-31): 6.3%Derived (calculated)
- Gross margin (FY 2025-12-31): 28.8%Derived (calculated)
- Return on assets (FY 2025-12-31): 4.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.42xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.13xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -11.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -65.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 5.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 18.3%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 10.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -4.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 17.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 27.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -5.4%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 7.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 7.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 0.1%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES 11SEC XBRL filing
- Operating cash flow (annual): USD 1.64BSEC XBRL filing
- Interest expense (annual): USD 224.1MSEC XBRL filing
- Revenue (annual): USD 13.95BSEC XBRL filing